Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Injection transendocardique de CSM allogénique chez des patients atteints de cardiomyopathie dilatée non ischémique (DCMII)

28 septembre 2026 mis à jour par: Joshua M Hare

Une étude de phase IIB randomisée, contrôlée par placebo et multicentrique de l'efficacité et de l'innocuité comparatives de l'injection transendocardique de CSM allogénique par rapport à un placebo chez des patients atteints de cardiomyopathie dilatée non ischémique

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

107

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • California
      • Stanford, California, États-Unis, 94304
        • Stanford University
    • Florida
      • Miami, Florida, États-Unis, 33136
        • University of Miami Miller School of Medicine
    • Kentucky
      • Louisville, Kentucky, États-Unis, 40202
        • University of Louisville
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Texas Heart Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Men and women aged 18 to 80 years (inclusive) at the time of signing the informed consent form.
  2. Diagnosis of NIDCM with left ventricular ejection fraction ≤45%.
  3. Appropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.
  4. Be a candidate for cardiac catheterization*
  5. Be willing to undergo DNA test.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy

  2. Clinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as electrocardiogram changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization

  3. Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries

  4. Valvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent*

  5. Aortic stenosis with valve area ≤ 1.5cm2*

  6. Cardiomyopathy due to acute Post-partum (within 6 months), Non-compaction*, or Hypertrophic* cardiomyopathy

  7. Cardiomyopathy due to known toxin (e.g amyloid) Note: anthracycline induced cardiomyopathy will be allowed

  8. QTc interval > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)

  9. Automated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent

  10. Have an estimated baseline glomerular filtration rate below the clinical site's institutional cutoff

  11. A hematologic abnormality during baseline testing as evidenced by hemoglobin < 9 g/dl; hematocrit < 30%; absolute neutrophil count < 2,000 or total WBC count more than 2 times upper limit of normal; or platelet values < 100,000/ul

  12. Have liver dysfunction, as evidenced by enzymes Aspartate Transaminase Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN

  13. Have a bleeding diathesis or coagulopathy (International Normalised Ratio (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions

  14. Be a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.

  15. Have a history of organ or cell transplant rejection

  16. Have a clinical history of malignancy within the past 12 months (i.e., subjects with prior malignancy must be disease free for 12 months), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma

  17. Drug and/or alcohol abuse or dependence within the past 9 months

  18. Be serum positive for HIV, hepatitis B surface antigen, or viremic hepatitis C

  19. Documented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to "Guidance to the PI" section with regards to LV thrombus, below)*

  20. Blood glucose levels (HbA1c) >10%

  21. Severe radiographic contrast allergy

  22. Known history of anaphylactic reaction to penicillin or streptomycin

  23. Hypersensitivity to dimethyl sulfoxide (DMSO)

  24. Non-cardiac condition with life expectancy < 1 year

  25. Acute stroke or transient ischemic attack within 3 months of enrollment

  26. Be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods

  27. Pacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)

  28. Presence of a pacemaker and/or ICD generator with any of the following limitations/conditions:

    • manufactured before the year 2000
    • leads implanted < 6 weeks prior to consent
    • non-transvenous epicardial or abandoned leads
    • subcutaneous ICDs
    • leadless pacemakers
  29. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent

  30. Other MRI contraindications (e.g. subject body habitus incompatible with MRI)

  31. Need for advanced heart failure therapy (e.g. IV inotropes)

  32. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial

  33. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up

(*) Applies to subjects receiving product via transendocardial administration only

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Genotype A administered with placebo Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Expérimental: Genotype A administered with hMSC Group

Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Comparateur placebo: Genotype B administered with placebo Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Expérimental: Genotype B administered with hMSC Group

Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Comparateur placebo: Genotype C administered with placebo Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.

Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

Expérimental: Genotype C administered with hMSC Group

Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.

allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in LVEF
Délai: Baseline, 12 months

Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)

Baseline, 12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in global ventricular strain
Délai: Baseline, 12 months

Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI

Baseline, 12 months
Change in left regional strain
Délai: Baseline, 12 months

Change in regional ventricular strain as assessed via cardiac HARP MRI

Baseline, 12 months
Left ventricular function concordance
Délai: 12 months

The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)

12 months
Change in LVEDVI
Délai: Baseline, 12 months

Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI

Baseline, 12 months
Change in LVESVI
Délai: Baseline, 12 months

Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI

Baseline, 12 months
Change in Maximal oxygen consumption (peak VO2)
Délai: Baseline, 12 months

Change in maximal oxygen consumption (peak VO2) as assessed via treadmill

Baseline, 12 months
Change in Exercise tolerance
Délai: Baseline, 12 months

Change in exercise tolerance as assessed as the distance covered via the six-minute walk test

Baseline, 12 months
Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score
Délai: Baseline, 12 months

Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.

Baseline, 12 months
Change in New York Heart Association (NYHA) Class
Délai: Baseline, 12 months

NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)

Baseline, 12 months
Percent change in flow mediated diameter
Délai: Baseline, 12 months

Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).

Baseline, 12 months
Change in EPC-CFU
Délai: Baseline, 12 months

Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

Baseline, 12 months
Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
Délai: Baseline, 12 months

Change in NT-proBNP as assessed via blood draw

Baseline, 12 months
Incidence of MACE
Délai: 12 months

Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician

12 months
Incidence of TE-SAEs
Délai: Day 30

Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician

Day 30

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Joshua Hare, MD, University of Miami

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 mai 2021

Achèvement primaire (Estimé)

1 avril 2027

Achèvement de l'étude (Estimé)

1 avril 2027

Dates d'inscription aux études

Première soumission

15 juillet 2020

Première soumission répondant aux critères de contrôle qualité

15 juillet 2020

Première publication (Réel)

20 juillet 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 20200566
  • CDMRP-PR191597 (Autre subvention/numéro de financement: US Department of Defense)
  • 20-02-134 (Autre identifiant: BRANY IRB)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner